The FDA has approved pivmecillinam (Pivya – Utility Therapeutics), an oral penicillin-class antibacterial drug, for treatment of uncomplicated urinary tract infections (uUTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis, or Staphylococcus saprophyticus in adult females. Pivmecillinam was approved by the FDA in 2024 but only recently became available in the US. It has been used in Europe for over 40 years.
ACUTE uUTI — The most common bacterial cause of acute uUTI in otherwise healthy nonpregnant women is E. coli; other common pathogens include...
- Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia
- Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome
- In Brief: A Bumetanide Nasal Spray (Enbumyst) for Edema
- In Brief: Ranitidine Returns
- In Brief: Rybelsus R2 Rebranded as Ozempic
- In Brief: Optune Pax — A Portable Device for Pancreatic Cancer (online only)
ISSUE
The FDA has approved Cardamyst (Milestone), a nasal spray formulation of the nondihydropyridine calcium channel blocker etripamil, for conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Cardamyst is the first product containing etripamil to be approved in the US. It is being marketed as the only FDA-approved, self-administered, rapid-acting treatment option for acute episodes of PSVT.
THE DISORDER — PSVT describes any of several regular, generally narrow-QRS complex tachycardias with sudden onset and termination. PSVTs commonly involve reentry within the AV node or between the AV node and an accessory pathway. Symptoms can include palpitations, dyspnea, chest discomfort, and, rarely, syncope. About 1 in 300 persons in the US are thought to have PSVT; older adults and females are at increased risk.1
Vagal …